|
1
|
Markman M: Current standards of care for
chemotherapy of optimally cytoreduced advanced epithelial ovarian
cancer. Gynecol Oncol. 131:241–245. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Pliarchopoulou K and Pectasides D:
Epithelial ovarian cancer: Focus on targeted therapy. Crit Rev
Oncol Hematol. 79:17–23. 2011. View Article : Google Scholar
|
|
3
|
He S, Niu G, Shang J, Deng Y, Wan Z, Zhang
C, You Z and Shen H: The oncogenic Golgi phosphoprotein 3 like
overexpression is associated with cisplatin resistance in ovarian
carcinoma and activating the NF-κB signaling pathway. J Exp Clin
Cancer Res. 36:1372017. View Article : Google Scholar
|
|
4
|
Roberts CM, Tran MA, Pitruzzello MC, Wen
W, Loeza J, Dellinger TH, Mor G and Glackin CA: TWIST1 drives
cisplatin resistance and cell survival in an ovarian cancer model,
via upregulation of GAS6, L1CAM, and Akt signalling. Sci Rep.
6:376522016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Roseman S: Reflections on glycobiology. J
Biol Chem. 276:41527–41542. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Iwamori M, Tanaka K, Kubushiro K, Lin B,
Kiguchi K, Ishiwata I, Tsukazaki K and Nozawa S: Alterations in the
glycolipid composition and cellular properties of ovarian
carcinoma-derived RMG-1 cells on transfection of the
α1,2-fucosyltransferase gene. Cancer Sci. 96:26–30. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhao Y, Lin B, Hao YY, Yan LM, Liu JJ, Zhu
LC and Zhang SL: The effects of Lewis(y) antigen content on drug
resistance to carboplatin in ovarian cancer line RMG-I. Prog
Biochem Biophys. 35:1175–1182. 2008.
|
|
8
|
Zhang F, Liu J, Lin B, Liu Q, Zhao Y, Zhu
L, Hao Y, Zhang S and Iwamori M: Increase in docetaxel-resistance
of ovarian carcinoma-derived RMG-1 cells with enhanced expression
of Lewis Y antigen. Int J Mol Sci. 12:7323–7334. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Liu J, Lin B, Hao Y, Qi Y, Zhu L, Li F,
Liu D, Cong J, Zhang S and Iwamori M: Lewis y antigen promotes the
proliferation of ovarian carcinoma-derived RMG-I cells through the
PI3K/Akt signaling pathway. J Exp Clin Cancer Res. 28:1542009.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hu Z, Gao J, Zhang D, Liu Q, Yan L, Gao L,
Liu J, Liu D, Zhang S and Lin B: High expression of Lewis y antigen
and CD44 is correlated with resistance to chemotherapy in
epithelial ovarian cancers. PLoS One. 8:e572502013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gao J, Hu Z, Liu J, Liu D, Wang Y, Cai M,
Zhang D, Tan M and Lin B: Expression of CD147 and Lewis y antigen
in ovarian cancer and their relationship to drug resistance. Med
Oncol. 31:9202014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhu LC, Gao J, Hu ZH, Schwab CL, Zhuang
HY, Tan MZ, Yan LM, Liu JJ, Zhang DY and Lin B: Membranous
expressions of Lewis y and CAM-DR-related markers are independent
factors of chemotherapy resistance and poor prognosis in epithelial
ovarian cancer. Am J Cancer Res. 5:830–843. 2015.PubMed/NCBI
|
|
13
|
Hu Z, Gao S, Gao J, Hou R, Liu C, Liu J,
Li B, Liu D, Zhang S and Lin B: Elevated levels of Lewis y and
integrin α5β1 correlate with chemotherapeutic drug resistance in
epithelial ovarian carcinoma. Int J Mol Sci. 13:15588–15600. 2012.
View Article : Google Scholar
|
|
14
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-ΔΔC(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
|
|
15
|
Zhu L, Hu Z, Liu J, Gao J and Lin B: Gene
expression profile analysis identifies metastasis and
chemoresistance-associated genes in epithelial ovarian carcinoma
cells. Med Oncol. 32:4262015. View Article : Google Scholar
|
|
16
|
Iwamori M, Iwamori Y, Kubushiro K,
Ishiwata I and Kiguchi K: Characteristic expression of
Lewis-antigenic glycolipids in human ovarian carcinoma-derived
cells with anticancer drug-resistance. J Biochem. 141:309–317.
2007. View Article : Google Scholar
|
|
17
|
Madjd Z, Parsons T, Watson NF, Spendlove
I, Ellis I and Durrant LG: High expression of Lewis y/b antigens is
associated with decreased survival in lymph node negative breast
carcinomas. Breast Cancer Res. 7:R780–R787. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gao L, Yan L, Lin B, Gao J, Liang X, Wang
Y, Liu J, Zhang S and Iwamori M: Enhancive effects of Lewis y
antigen on CD44-mediated adhesion and spreading of human ovarian
cancer cell line RMG-I. J Exp Clin Cancer Res. 30:152011.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yan LM, Lin B, Zhu LC, Hao YY, Qi Y, Wang
CZ, Gao S, Liu SC, Zhang SL and Iwamori M: Enhancement of the
adhesive and spreading potentials of ovarian carcinoma RMG-1 cells
due to increased expression of integrin alpha5beta1 with the Lewis
Y-structure on transfection of the alpha1,2-fucosyltrans-ferase
gene. Biochimie. 92:852–857. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tan M, Zhu L, Zhuang H, Hao Y, Gao S, Liu
S, Liu Q, Liu D, Liu J and Lin B: Lewis Y antigen modified CD47 is
an independent risk factor for poor prognosis and promotes early
ovarian cancer metastasis. Am J Cancer Res. 5:2777–2787.
2015.PubMed/NCBI
|
|
21
|
Gao S, Liu Q, Wang X, Lin B and Zhang S:
Effects of Lewis Y antigen on the gene expression of multiple drug
resistance-associated proteins in human ovarian cancer RMG-I-H
cells. Med Oncol. 27:960–967. 2010. View Article : Google Scholar
|
|
22
|
Wang C, Yan L, Wang Y, Lin B, Liu S, Li Q,
Gao L, Zhang S and Iwamori M: Overexpression of Lewis(y) antigen
protects ovarian cancer RMG-1 cells from carboplatin-induced
apoptosis by the upregulation of Topo-I and Topo-II β. Anat Rec
(Hoboken). 294:961–969. 2011. View
Article : Google Scholar
|
|
23
|
Wang XQ, Sun P, O'Gorman M, Tai T and
Paller AS: Epidermal growth factor receptor glycosylation is
required for ganglioside GM3 binding and GM3-mediated suppression
[correction of suppresion] of activation. Glycobiology. 11:515–522.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liu JJ, Lin B, Hao YY, Li FF, Liu DW, Qi
Y, Zhu LC, Zhang SL and Iwamori M: Lewis(y) antigen stimulates the
growth of ovarian cancer cells via regulation of the epidermal
growth factor receptor pathway. Oncol Rep. 23:833–841.
2010.PubMed/NCBI
|
|
25
|
Li FF, Liu JJ, Liu DW, Lin B, Hao YY, Cong
JP, Zhu LC, Gao S, Zhang SL and Iwamori M: Lewis Y regulates
signaling molecules of the transforming growth factor β path way in
ovarian carcinoma derived RMG-I cells. Int J Oncol. 40:1196–1202.
2012. View Article : Google Scholar
|
|
26
|
Zhuang H, Gao J, Hu Z, Liu J, Liu D and
Lin B: Co-expression of Lewis y antigen with human epididymis
protein 4 in ovarian epithelial carcinoma. PLoS One. 8:e689942013.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lee T, Guo K, Li S, Qin S and Liu S:
Effects of ANXA4 on cell adhesive ability and expression of
adhesion-related genes in hepatocellular carcinoma MHCC97H cell
line. J Clin Trials. 31:588–591. 2013.
|
|
28
|
Matsuzaki S, Serada S, Morimoto A, Ueda Y,
Yoshino K, Kimura T and Naka T: Annexin A4 is a promising
therapeutic target for the treatment of platinum-resistant cancers.
Expert Opin Ther Targets. 18:403–414. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Choi CH, Sung CO, Kim HJ, Lee YY, Song SY,
Song T, Kim J, Kim TJ, Lee JW, Bae DS, et al: Overexpression of
Annexin A4 is associated with chemoresistance in papillary serous
adenocar-cinoma of the ovary. Hum Pathol. 44:1017–1023. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lin LL, Huang HC and Juan HF: Revealing
the molecular mechanism of gastric cancer marker Annexin A4 in
cancer cell proliferation using exon arrays. PLoS One.
7:e446152012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kelly MP, Lee FT, Tahtis K, Smyth FE,
Brechbiel MW and Scott AM: Radioimmunotherapy with alpha-particle
emitting 213Bi-C-functionalized
trans-cyclohexyl-diethylenetriamine-pentaacetic acid-humanized
3S193 is enhanced by combination with paclitaxel chemotherapy. Clin
Cancer Res. 13:5604s–5612s. 2007. View Article : Google Scholar
|
|
32
|
Baldus SE, Mönig SP, Zirbes TK, Thakran J,
Köthe D, Köppel M, Hanisch FG, Thiele J, Schneider PM, Hölscher AH,
et al: Lewis(y) antigen (CD174) and apoptosis in gastric and
colorectal carcinomas: Correlations with clinical and prognostic
parameters. Histol Histopathol. 21:503–510. 2006.PubMed/NCBI
|
|
33
|
Azuma Y, Ito M, Taniguchi A and Matsumoto
K: Expression of cell surface Lewis X and Y antigens and FUT4 mRNA
is increased in Jurkat cells undergoing apoptosis. Biochim Biophys
Acta. 1672:157–163. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Azuma Y, Kurusu Y, Sato H, Higai K and
Matsumoto K: Increased expression of Lewis X and Y antigens on the
cell surface and FUT 4 mRNA during granzyme B-induced Jurkat cell
apoptosis. Biol Pharm Bull. 30:655–660. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Gao N, Liu J, Liu D, Hao Y, Yan L, Ma Y,
Zhuang H, Hu Z, Gao J, Yang Z, et al: c-Jun transcriptionally
regulates alpha 1, 2-fucosyltransferase 1 (FUT1) in ovarian cancer.
Biochimie. 107:286–292. 2014. View Article : Google Scholar : PubMed/NCBI
|
